CA-CEPTON/ALP.LAB
22.2.2021 14:02:12 CET | Business Wire | Press release
Cepton, a leading provider of intelligent, lidar-based solutions, and the Austrian Industry and Testing Alliance ALP.Lab have partnered to build lidar-equipped testing environments for studying complicated road driving situations. For the first time in Austria, this project will deliver real-world traffic data from complex urban and rural alpine intersections.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005304/en/
As an alliance of automotive suppliers such as Magna and AVL, and as a partner to scientific organizations like Virtual Vehicle Research, Joanneum Research and Graz University of Technology, ALP.Lab delivers real-life data on complex traffic situations to test the capabilities of the autonomous driving systems, and helps enable solutions to reduce accidents and improve traffic flows.
From narrow, foggy streets covered in snow, to cyclists overtaking a tram in the middle of an intersection, Austria, with its mountainous landscape, sees varied road driving scenarios and faces unique challenges in ensuring vehicle and pedestrian safety. Difficult traffic scenarios could pose obstacles for the seamless deployment of autonomous mobility solutions. Compiling a realistic database of different driving scenarios is, therefore, pivotal to the testing and verification of advanced driver assistance systems (ADAS) and autonomous vehicles (AVs), to ensure that they work well in complex environments.
Through this new partnership, ALP.Lab has deployed Cepton’s Helius™ Smart Lidar System to capture real-time, 3D traffic data to support the training of artificial intelligence (AI) algorithms used for the scenario-based testing of ADAS and AV features. Additionally, the collected data will make it possible to predict vehicle trajectories at intersections and enable traffic data analysis for traffic flow optimization.
As part of the Helius system, a number of Vista®-P60 lidar sensors from Cepton have been installed at the corners of road intersections and traffic roundabouts, complementing other sensor types including radar and other types of optical sensors. For traffic monitoring and analysis applications, lidars perform well in many critical cases where other sensor types struggle. Lidars offer 24/7 availability thanks to their superior perception capabilities in various lighting conditions, such as night-time, shadows and the glare of strong headlights. Lidars also offer much higher angular resolution compared to radars and minimize false negatives and false positives. The Vista-P60 lidars, powered by Cepton’s patented Micro Motion Technology (MMT®), offer a high detection range of 200 m at 30% reflectivity and an angular resolution of 0.25°, making it possible to accurately detect each arriving and departing vehicle and pedestrian at a distance of up to ~170 meters around the intersections.
The advanced Helius perception software adds an additional layer of intelligence to the lidar data from the Vista-P60. Helius takes the point cloud data from a connected network of Vista-P60 sensors and delivers real-time, 3D information on object dimensions, locations and velocities. This enables Helius to accurately track and classify the different objects involved in a traffic situation. As Helius and the other sensors used by ALP.Lab only capture anonymized data, it protects the privacy of pedestrians and vehicles while feeding ALP.Lab rich traffic data for deeper analysis.
The Helius Smart Lidar system offers optimal ease of integration. The rotation-free, mirrorless and frictionless design makes Vista-P60 sensors very durable and embeddable. The rugged sensor housing is designed to withstand harsh outdoor environments and cold climates, resulting in product robustness and longevity to drive down maintenance costs. With the pre-installed Helius software running on an edge computer, which connects a scalable network of lidar sensors, Helius is a truly plug-and-play system that is extremely easy to set up and scale up.
“We primarily selected Cepton's lidar solutions because of their durability and precise detection capabilities even at high vehicle speeds. With the information the lidar sensors provide, our data is as close to real-life as it gets. Therefore, we are able to create enhanced simulation and AV testing environments as well as detailed analyses of the traffic flow,” said Christian Schwarzl, Director of Testing and Validation from ALP.Lab. “There is amazing synergy between Cepton and ALP.Lab, as we share the same goal of making ADAS and AV features available to the mass market and to improve the safety of vulnerable road users.”
“Lidar plays a crucial role in the future of autonomous mobility, by not only serving as the 'eyes' of vehicles but also bringing intelligence to the traffic infrastructure supporting safe autonomy. In order to make ADAS and AV capabilities available to the broader public, it is crucial to gather information on traffic scenarios that all vehicles are likely to be confronted with, in order to generate proper testing environments and ensure safer roads,” said Dr. Jun Pei, CEO of Cepton. “So, we are excited to partner with ALP.Lab in this endeavor, and we are gratified that our technology can contribute significantly to its success.”
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
About ALP.Lab
ALP.Lab is the Austrian Light Vehicle Proving Region for Automated Driving and provides comprehensive services for safe and secure testing of automated driving technologies.
Founded in 2017, ALP.Lab provides an integrated test chain for automated driving functions and vehicles, enabling testing activities in both the virtual and real world. ALP.Lab offers a holistic traffic monitoring solution to create testing scenarios out of real-life driving behavior in primary, secondary, and urban road networks. Further, ALP.Lab provides a professional testing team for Euro-NCAP-compliant ADAS/AD testing, including extensive testing equipment and different proving grounds. A unique mobile HIL (hardware-in-the-loop) system facilitates complex sensor testing and validation.
A strong network of industrial and scientific partners support the capabilities of ALP.Lab for safe and secure testing of any autonomous mobility solutions. Creating value for their customers by providing high-end testing facilities and real-time traffic data is the main driver for the Austrian Light Vehicle Proving Region for Automated Driving.
For more information, visit www.alp-lab.at and follow us on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005304/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
